Upload
muralikrishna-chv
View
360
Download
0
Embed Size (px)
Citation preview
Thrombolysis in acute ischaemicstroke
DR.MURALI KRISHNA.CH.V
MD.DM
CONSULTANT NEUROPHYSICIAN
AWARE GLOBAL HOSPITAL,HYDERABAD
• Burden of stroke
• Types ,risk factors.
• Time is brain
• Evidence based thrombolysis.
• How big is the problem of STROKE?
Stroke accounts for 10% of all-cause mortality
Cancer
12%
Stroke
10%
Accidents
Respiratory infections 7%
HIV/AIDS 5%
Chronic obstructive pulmonary
disease 5%
Perinatal causes
DiarrhoeaTuberculosis
3%3%4%
2%
Malaria
Coronary heart disease
13%
American Stroke Association. Heart Disease and Stroke Statistics 2004
9%
27%
Other causes
Since 80s, a significant increase (> 2-fold ) has been noticed in incidence of stoke : 1–2 /1.000 people in USA, 2–2.5/1.000 in Western και 3–3.5/1.000 in Eastern Europe
What is specific to stroke in India?
• Analysis of community surveys from different regions of India shows a
crude stroke prevalence rate of about 203 per 100,000 population
above 20 years of age, with recent study done in eastern population
reaching 504 per 100,000 population
• Most studies carried out in India show that about 10% to 15% of
strokes occur in the population below 40 years, which is a higher
proportion compared with other countries
ACNR •2007
STROKE: A Major Problem for Public Health
increased ~65% until 2025
Broderick JP et al. Stroke 2004;35:205-211
Estimated number of strokes in USA during 2002-2025
Types of ischemic strokes
• Large artery disease ( cervical ICA / Subclavian /
Vertebral): artery to artery embolus / occlusion
• Medium sized artery disease (MCA/ ACA/ Basilar/
PCA) : artery to artery embolus / occlusion
• Small vessel disease (perforators) : occlusion due to
arteriosclerosis (HT)
• Cardiogenic embolus
• Hypercoagulable states
Risk Factors for StrokeModifiable
• Hypertension• Type 2 Diabetes• Cardiac disease• Atrial fibrillation• TIA/prior stroke• Dyslipidemia• Cigarette smoking• Alcohol/cocaine abuse• Physical inactivity• Carotid stenosis• Sickle cell disease• Obesity
Non-modifiable
• Older Age
• Gender
• Race/ethnicity
• Heredity
Circulation. 2001;103:163-182.
2.64
5.4
8.4
1.1 2
19.1
22.4
14.8
27
6.3
3.5
0
5
10
15
20
25
30
A B C D E F
Est
imat
ed 1
0-Y
ear R
ate
(%)
Men Women
10yr risk for Stroke in Adults 55 yrs old according to basic Risk Factors
(Framingham Heart Study)
A B C D E F
Systolic BP 95-105 130-148 130-148 130-148 130-148 130-148 mmHg
Diabetes no no yes yes yes yes
Smoking no no no yes yes yes
Previous AF no no no no yes yes
Previous CVD no no no no no yes
Stroke 1991;22:312-318
A very selfish organ
• The brain requires
20 % of
the total blood
pumped
by the heart.
• No fat for storage
in the brain
• Requires constant
supply of oxygen and glucose.
Stroke ,2006
Every minute if stroke is untreated, the average patient loses 1.9 million neurons, 13.8
billion synapses, and 12 km (7 miles) of axonal fibers.
Each hour in which treatment fails to occur, the brain loses as many neuron as it does in
almost 3.6 years of normal aging.
STROKE IS A DYNAMIC ONGOING PROCESS !!! Every minute 20 lakh neurons die !
PATHOPHYSIOLOGY OF STROKE & PENUMBRA
DWI-PWI …. Mismatch
“Time is Brain”
• Treatment of stroke is a salvage procedure.
Time of treatment in stroke is important for outcome
TOT NNT
108
MANY EVIDENCE BASED ACUTE STROKE THERAPIES AVAILABLE
STROKE UNIT IV THROMBOLYSIS Decom. Craniectomy
Mech. Thrombolysis IA – Thrombolysis & CE PTBA & Stenting
Golden period for stroke Rx esp. 90 min
IV thrombolysis with rt-PA in eligible patients is the standard care according to many national & International guidelines. CLASS I LEVEL A EVIDENCE
1) AHA guidelines2) EUSI guidelines3) ACC guidelines4) ACEP guidelines5) Karolinska stroke update consensus statement6) RCP guidelines (UK)7) Indian stroke association guidelines
IV Thrombolysis 0-3 hrs
- Prospective, randomized, double-blind trial
- 624 patients : half treated within 90 minutes, half treated within 91 to 180 minutes
- t-PA dose : 0.9 mg/kg, maximum dose : 90mg, 10% as IV bolus, remainder via 1-hour infusion
-- Careful attention to BP : < or equal to 185/110
- No ACs or antiplatelet agents for 24 hours
THE HALLMARK STUDYNINDS t-PA Study:
rt-PA Studies: NINDS Parts 1 and 2 – Results
NINDS Investigators. N Engl J Med 1995; 333 (24): 1581–1587.
placebo
rt-PA
modified Rankin Scale (mRS)
17.3 21.4 8.9 12.5 15.5 7.1 17.3
9.1 17.0 12.1 13.3 20.0 7.9 20.6
12.6% more rt-PA treated patients have favourable outcome
3% less rTPA treated patients are dead
0 1 2 3 4 5 6
And this was inspite of a 6.4% risk of ICH in the rTPA group
NINDS TPA Stroke Trial
Global outcome statistic: OR=1.7, 50% v. 38%= 12% benefit
Excellent outcome at 3 months on all scales
52%
38%43%
26%
45%
31%34%
21%
0%
10%
20%
30%
40%
50%
60%
Barthel
Index
Rankin
Scale
Glasgow
Outcome
NIHSS
score
TPA
Placebo
N Engl J Med 1995;333:1581-7
tPa vs time
Number of Patients Who Benefit and Are Harmed per 100
Patients tPA Treated in Each Time Window
27.0
22.2
15.9
5.0
1.3 2.45.0
7.1
0.0
5.0
10.0
15.0
20.0
25.0
30.0
0-90 91-180 181-270 271-360
Benefit
Harm
--Lansberg et al, Stroke 2009
Extended Time Frame for IVT : 3- 4.5 hrs
ECASS- 3
• Window period 3-4.5 hr
• 821 patients were randomized to IV tPA or placebo.
• Major symptomatic hemorrhages occurred in 2.4% of the tPA group versus 0.2% of the placebo group, with no increase in mortality.
• The proportion of patients with minimal or no disability increased from 45% with placebo to 52% with tPA, a 7% absolute improvement.
• The number needed to treat for 1 more patient to have a normal or near normal outcome was 14,
• and the number needed to treat for 1 more patient to have an improved outcome was 8.
• Overall, for every 100 patients treated within the 3- to 4.5-hour window, 16 had a better outcome as a result and 3 had a worse outcome.
• Iv Tpa 3-5 hrs-Vs placibo - ATLANTIS TRIAL-
• Excellent recovery at 90 days -34% vs 31%
• SICH IN First 10 days- 7% vs 1 %.
• Iv tpa up to 6hrs- ECASS 2
• mrs > 2 more in tpa group but not stat significant
• 10% increase in parenchymal hemorrage.
Tpa -age
tpa vs other drugs
IV urokinase
IV streptokinase
IV rt-PA
IV streptokinase
+ aspirin
IA pro-urokinase
IA urokinase
IV desmoteplase
Death or dependency at the end of follow-up
Total
0.91 (0.64, 1.42)
0.94 (0.72, 1.24)
0.77 (0.47, 0.89)
1.09 (0.49, 1.72)
0.55 (0.31, 1.00)
0.57 (0.28, 1.14)
0.85 (0.53, 1.38)
0.82 (0.73, 0.91)
All drugs and rt-PA Summary of effects, 2008; ORs (95% CI)
SICH Late Death or
(incl fatal) Death Dependency
All drugs 3.3 1.3 * 0.8 *
n=7152 2.7 - 4.1 1.1 - 1.5 0.7 - 0.9
p<0.00001 p=0.06 p<0.0001
rt-PA 3.1 1.1 0.8 *
n=3977 2.3 - 4.0 1.0 - 1.4 0.7 - 0.9
p<0.00001 p=0.16 p<0.0001
* Significant heterogeneity confounds interpretation
rt-PA trials: 2003 versus 2008 ORs (95% CI)
SICH Late Death or
(incl fatal) Death Dependency
2003 3.1 1.2 * 0.8 *
n=2955 2.3 - 4.2 0.9 - 1.5 0.7 - 0.9
p<0.00001 p=0.14 p=0.003
2008 3.1 1.1 0.8 *
n=3977 2.3 - 4.0 1.0 - 1.4 0.7 - 0.9
p<0.00001 p=0.16 p<0.0001
* significant heterogeneity confounds interpretation
IA Or iv TPA Or BOTH
Intraarterial TPA.
IA-TPA in selected pts. In < 6 hours due to MCA
& BA occlusion
In BA occlusion it can be given even after > 12
hours.
In future IA-TPA will be rewarding.
PROACT II Trial
• First phase III trial of I.A.T.
• 9 mg Pro-UK + heparin(121) vs IV
heparin(59) within 6h.
• 180 patients, M1 or M2 MCA occlusion.
• Average NIHSS 17.
• Median time to I.A.T 5.7 hours.
PROACT II Trial
• mRS < 2 : 40% VS 25% (+- SIG)
• Recanalisation at 2h: 66% vs 18%
• Hemorrhage at 36h:
– all: 46% vs 16%
– symptomatic: 10% vs 2%
• No difference in mortality
IA vs IV TPA
Advantages of IA over IV
• Wider window : 6 hrs for ant circ & 12-24 hrs for post circ
• Greater recanalisation rate : 65 – 70% (only 30% in IV)
• Especially in large vessel occlusions, i.e ICA, MCA stem, Basilar
• Lesser dose injected directly into clot
• Underlying atheromatous disease can be addressed, e.g intracranial stenting / heparin for unstable plaque
I.A.T. Potential
Disadvantages
• Catheter manipulation
• Systemic heparinisation
• Delay in initiation of thrombolysis
• Skilled facilities
IV plus IA thrombolysisStroke Bridging Trial
• Lewandowski CA et al Stroke 1999
• Randomized pilot study. 35 patients
• tPA IV 0.6 mg/Kg then IA 20 mg
• Symptomatic hemorrhage: 11% both
groups
• Recanalisation at 2h:
– All: 55% IV/IA vs 10% IA
– M1: 100% IV/IA vs 67% (PROACT)
tpa + sonothrombolysis
• CCLOTBUST TRIAL.
• IV tPa + u/s therapy vs iv tPa alone
• Better outcome with sonothrmbolysis i.e better
recanalisation after 2hr.
MANAGEMENT OF ACUTE ISCHEMIC
STROKE -AHA/ASA GUIDELINES
Class I
Benefit >>> Risk
Procedure/ Treatment
SHOULD be
performed/
administered
Class IIa
Benefit >> Risk
Additional studies
with focused
objectives needed
IT IS REASONABLE
to perform
procedure/administer
treatment
Class IIb
Benefit ≥ Risk
Additional studies with
broad objectives
needed; Additional
registry data would be
helpful
Procedure/Treatment
MAY BE
CONSIDERED
Class III
Risk ≥ Benefit
No additional studies
needed
Procedure/Treatment
should NOT be
performed/administered
SINCE IT IS NOT
HELPFUL AND MAY
BE HARMFUL
Level A: Recommendation based on evidence from multiple randomized trials or meta-analyses
Multiple (3-5) population risk strata evaluated; General consistency of direction and magnitude of
effect
Level B: Recommendation based on evidence from a single randomized trial or non-randomized studies
Limited (2-3) population risk strata evaluated
Level C: Recommendation based on expert opinion, case studies, or standard-of-care
Very limited (1-2) population risk strata evaluated
should
is recommended
is indicated
is useful/effective/
beneficial
is reasonable
can be useful/effective/
beneficial
is probably recommended or
indicated
may/might be considered
may/might be reasonable
usefulness/effectiveness is
unknown /unclear/uncertain
or not well established
is not recommended
is not indicated
should not
is not
useful/effective/beneficial
may be harmful
IV Recombinant Tissue Plasminogen
Activator (r-tPA) for Patients
With Acute Ischemic Stroke
In patients with acute ischemic stroke in whom
treatment can be initiated within 3 h of symptom
onset, we recommend IV recombinant tissue
plasminogen activator (r-tPA) over no IV
r-tPA (Grade 1A).
IV Recombinant Tissue Plasminogen Activator (r-
tPA) for Patients
With Acute Ischemic Stroke
In patients with acute ischemic stroke in whom
treatment can be initiated within 4.5 h but not
within 3 h of symptom onset, we suggest IV r-
tPA over no IV r-tPA (Grade 2C).
Intraarterial Thrombolysis in Patients With
Acute Ischemic Stroke
In patients with acute ischemic stroke due to proximal
cerebral artery occlusions who do not meet eligibility
criteria for treatment with IV r-tPA, we suggest
intraarterial (IA) r-tPA initiated within 6 h of symptom
onset over no IA r-tPA (Grade 2C).
Thank u